- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05346809
Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
February 1, 2024 updated by: Divaya Bhutani
Randomized Phase 2 Trial of Isatuximab During Autologous Stem Cell Collection and Transplantation Period in Patients With Multiple Myeloma, Relapsed Hodgkin's and Non-Hodgkin's Lymphoma
The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation.
The investigators will see if Isatuximab makes changes to the immune system so that upon recovery from the transplant, the immune system can fight the cancer.
This study will have two arms.
On one arm (control arm), participants will receive standard transplant procedures and on the other arm (experimental arm), participants will receive Isatuximab in addition to the standard transplant procedures.
The assignment to these arms is done randomly (determined by chance, like flipping a coin) by a computer.
Each participant will have about 66% chance of getting on the experimental arm and about 33% chance of getting on the control arm.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
Relapse post-autologous stem cell transplantation (ASCT) remains a major challenge in the treatment of multiple myeloma (MM) and Lymphoma.
The immune reconstitution post-ASCT has a major impact on the outcomes of ASCT, however effective methods to improve upon immune reconstitution have not been developed and the use of novel immunomodulators remains relatively unexplored.
In addition, numerous studies have demonstrated the profound impact of graft composition on transplant outcomes, but not a single prospective study has addressed this issue successfully.
In this study, the investigators intend to test a novel double pronged method of changing the immune repertoire post ASCT by modifying graft composition and improving effector T cell recovery and function post ASCT.
In this study, the investigators intend to generate new information on immune modulation post-ASCT.
In addition, the CD38 antibodies have not been evaluated as therapy for B-cell non-Hodgkin Lymphoma (NHL).
If this study shows significant immunomodulator activity of this approach, cluster of differentiation 38 (CD38) antibodies could be further evaluated in combination with ASCT in NHL.
Study Type
Interventional
Enrollment (Estimated)
39
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Research Nurse Navigator
- Phone Number: 212-342-5162
- Email: cancerclinicaltrials@cumc.columbia.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Recruiting
- Columbia University
-
Principal Investigator:
- Divaya Bhutani, MD
-
Contact:
- Research Nurse Navigator
- Phone Number: 212-342-5162
- Email: cancerclinicaltrials@cumc.columbia.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
Following diagnoses are eligible for inclusion in the study:
A) Multiple Myeloma with ASCT used as consolidation after first line induction therapy or at first relapse.
B) Relapsed/Refractory Hodgkin's disease
C) Non-Hodgkin's Lymphomas as follows
- Relapsed/Refractory Diffuse large B cell lymphoma
- Relapsed/Refractory indolent or relapsed/refractory transformed indolent B cell lymphomas as consolidation after second line therapy
- Mantle Cell lymphoma as consolidation after first-line therapy
- Peripheral T cell lymphoma as consolidation after first-line therapy or at relapse or primary refractory disease
- Patients undergoing first ASCT will be eligible for the study.
- Any prior therapy for the malignancy except CD38 antibody within the last 12 months is allowed.
- Age ≥18 years
- Life expectancy of greater than 6 months.
Exclusion Criteria:
- Previously exposure to a CD38 antibody during the last 12 months.
- Participants who are receiving any other investigational agents concurrently or received any investigational agent within the last 8 weeks.
- History of severe allergic reactions or anaphylaxis attributed to compounds of similar chemical or biologic composition to Isatuximab.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnant and Lactating women
- HIV-positive status due to increased risk of infection when treated with immunosuppressive therapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Isatuximab and Standard Procedures
Subjects will receive the study drug Isatuximab in addition to standard procedures for transplant
|
Isatuximab in IV form 10 mg/kg doses
Other Names:
|
Experimental: Standard procedures
Subjects will receive standard procedures for transplant.
|
Standard procedures (standard of care) for transplant
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the total lymphocyte count
Time Frame: Day 30
|
Change in total lymphocyte count measured from blood sample
|
Day 30
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Adverse Events
Time Frame: Up to 1 year
|
The number of adverse events recorded for participants using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
|
Up to 1 year
|
Percentage of participants with absolute lymphocyte count >500 cells/microliter
Time Frame: Day 30
|
Percentage of participants with an absolute lymphocyte count of >500 cells/microliter on Day 30 post transplant
|
Day 30
|
CD8 and CD4 Subsets
Time Frame: Up to 1 year
|
Immune cell phenotyping ( cluster of differentiation 8 (CD8) and cluster of differentiation 4 (CD4) subsets) in the peripheral blood using flow cytometry based analysis
|
Up to 1 year
|
Percentage of activated B and T regulatory cells
Time Frame: Up to 1 year
|
Percentage of activated B and T regulatory cells in the peripheral blood
|
Up to 1 year
|
Percentage of activated helper and effector T cells
Time Frame: Up to 1 year
|
Percentage of activated helper and effector T cells in the peripheral blood
|
Up to 1 year
|
Percentage of Natural Killer (NK) cells
Time Frame: Up to 1 year
|
Percentage of NK cells in the peripheral blood
|
Up to 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Divaya Bhutani, Columbia University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 31, 2023
Primary Completion (Estimated)
March 1, 2025
Study Completion (Estimated)
March 1, 2025
Study Registration Dates
First Submitted
April 20, 2022
First Submitted That Met QC Criteria
April 20, 2022
First Posted (Actual)
April 26, 2022
Study Record Updates
Last Update Posted (Estimated)
February 2, 2024
Last Update Submitted That Met QC Criteria
February 1, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Lymphoma
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Hodgkin Disease
- Lymphoma, Non-Hodgkin
Other Study ID Numbers
- AAAT7444
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
IGM Biosciences, Inc.ADC Therapeutics S.A.Active, not recruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Zhejiang UniversityShanghai First Song Therapeutics Co., LtdNot yet recruitingHodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell LymphomaChina
-
SymBio PharmaceuticalsCompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, DiffuseJapan, Korea, Republic of
-
Massachusetts General HospitalTG TherapeuticsTerminatedLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular... and other conditionsUnited States, Canada, Australia, Puerto Rico
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Diffuse Large B-cell LymphomaUnited States
Clinical Trials on Isatuximab
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingMultiple Myeloma | Monoclonal Gammopathy of Undetermined Significance | Cryoglobulinemic Vasculitis
-
Thomas Martin, MDWithdrawnRefractory Multiple Myeloma | Relapsed Multiple Myeloma
-
Firas El Chaer, MDRecruitingHematologic Malignancy | Platelet RefractorinessUnited States
-
Memorial Sloan Kettering Cancer CenterSanofiRecruitingBlood Cancer | Refractory Immune CytopeniasUnited States
-
Columbia UniversityGenzyme, a Sanofi CompanyRecruitingMonoclonal GammopathyUnited States
-
Assistance Publique - Hôpitaux de ParisNot yet recruiting
-
SanofiTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)United Kingdom, Belgium, Netherlands, France, United States, Germany, Hungary, Italy
-
Karolinska InstitutetSanofi; XNK Therapeutics AB, SwedenRecruiting
-
SanofiCompleted
-
SanofiCompletedPlasma Cell MyelomaUnited States, Czechia, France